Utilization of Beta Blockers in the Pediatric Population: An Updated Descriptive Analysis Read more about Utilization of Beta Blockers in the Pediatric Population: An Updated Descriptive Analysis
Utilization of Beta Blockers in the Pediatric Population: A Descriptive Analysis Read more about Utilization of Beta Blockers in the Pediatric Population: A Descriptive Analysis
Baricitinib or Tocilizumab Use in Hospitalized Patients with a COVID-19 Diagnosis: A Descriptive Analysis Read more about Baricitinib or Tocilizumab Use in Hospitalized Patients with a COVID-19 Diagnosis: A Descriptive Analysis
Treatment and Care Received by Children Hospitalized with COVID-19 in a Large Hospital Network in the United States, February 2020 to September 2021 Read more about Treatment and Care Received by Children Hospitalized with COVID-19 in a Large Hospital Network in the United States, February 2020 to September 2021
Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis Read more about Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis
Six Years of FDA's Postmarket Active Risk Identification and Analysis System (ARIA) in the Sentinel Initiative: Implications for Real World Evidence Generation Read more about Six Years of FDA's Postmarket Active Risk Identification and Analysis System (ARIA) in the Sentinel Initiative: Implications for Real World Evidence Generation
Switching Patterns of Immediate-Release Forms of Generic Mixed Amphetamine Salts Products Among Privately and Publicly Insured Individuals Aged 15-64 Years in the United States, 2013-2019 Read more about Switching Patterns of Immediate-Release Forms of Generic Mixed Amphetamine Salts Products Among Privately and Publicly Insured Individuals Aged 15-64 Years in the United States, 2013-2019
Alosetron and Eluxadoline Use: A Descriptive Analysis Read more about Alosetron and Eluxadoline Use: A Descriptive Analysis
Dupixent (Dupilumab) Utilization Patterns: A Descriptive Analysis Read more about Dupixent (Dupilumab) Utilization Patterns: A Descriptive Analysis